New pill aims to relieve long COVID misery in major trial

NCT ID NCT05999435

First seen Jan 07, 2026 · Last updated May 01, 2026 · Updated 17 times

Summary

This study tested an oral medication called LAU-7b in 272 adults with Long COVID who had moderate to severe symptoms lasting at least 12 weeks after their COVID-19 infection. The goal was to see if the drug could improve physical function and reduce symptoms compared to a placebo. The trial was double-blind, meaning neither participants nor doctors knew who got the real drug.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LONG COVID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CIUSS du Saguenay-Lac-St-Jean - Hôpital Chicoutimi

    Chicoutimi, Quebec, G7H 5H6, Canada

  • Centre Hospitalier de l'Université de Sherbrooke

    Sherbrooke, Quebec, J1H 5N4, Canada

  • Diex Recherche Québec Inc.

    Québec, Quebec, G1V 4T3, Canada

  • Institut de Recherches Cliniques de Montréal

    Montreal, Quebec, H2W 1R7, Canada

  • Montreal General Hospital

    Montreal, Quebec, H3G 1A4, Canada

Conditions

Explore the condition pages connected to this study.